Sign in or create an account to add this stock to your watchlist.
About Acceleron Pharma (NASDAQ:XLRN)
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200
Debt
Debt-to-Equity RatioN/A
Current Ratio23.21
Quick Ratio23.21
Price-To-Earnings
Trailing P/E Ratio-13.34
Forward P/E Ratio-15.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.48 million
Price / Sales121.38
Cash FlowN/A
Price / CashN/A
Book Value$7.73 per share
Price / Book4.62
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-839.98%
Return on Equity-34.52%
Return on Assets-32.40%
Miscellaneous
Employees139
Outstanding Shares45,780,000
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma (NASDAQ:XLRN) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.06. The biopharmaceutical company had revenue of $3.23 million for the quarter, compared to analyst estimates of $3.77 million. Acceleron Pharma had a negative return on equity of 34.52% and a negative net margin of 839.98%. Acceleron Pharma's revenue for the quarter was down 12.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.66) earnings per share. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
14 brokers have issued 12-month target prices for Acceleron Pharma's stock. Their predictions range from $33.00 to $69.00. On average, they expect Acceleron Pharma's stock price to reach $51.0769 in the next year. View Analyst Ratings for Acceleron Pharma.
What are Wall Street analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
- 1. Cann analysts commented, "While we have not modeled ACE-083 into our outlook for Acceleron by 2022, Fast Track designation has the potential to move the timeline for ACE-083 forward. Based on this and recently released positive results for ACE-083, we believe this program will continue to advance and will likely become a marketed drug." (5/1/2018)
- 2. HC Wainwright analysts commented, "Preliminary ACE-083 Phase 2 Data Demonstrates Serious Gains in FSHD; Part 2 Current Underway Data demonstrates dose-dependent increases in total muscle volume. This morning, Acceleron Pharma announced preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) from the 150 and 200mg arms at the American Academy of Neurology (AAN) 70th Annual Meeting, which is being held in Los Angeles. ACE-083 demonstrated dose-dependent increases in total muscle volume in both the Tibalis Anterior (TA) and Biceps Brachii (BB) muscle cohorts, with a 15-20% increase observed at the higher dose level. In addition, a decrease in fat fraction was observed in both cohorts, however, it was more notable in the TA cohort. With regard to safety, ACE-083 was safe and generally well-tolerated in subjects for up to three months, which included five doses." (4/26/2018)
- 3. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (8/9/2017)
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
- Mr. Kevin F. McLaughlin, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 62)
- Dr. Ravindra Kumar Ph.D., Chief Scientific Officer and Sr. VP (Age 58)
- Dr. Matthew L. Sherman, Chief Medical Officer & Exec. VP (Age 62)
Has Acceleron Pharma been receiving favorable news coverage?
Media headlines about XLRN stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a coverage optimism score of 0.10 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.39 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.81%), Farallon Capital Management LLC (3.06%), Westfield Capital Management Co. LP (3.00%), Eagle Asset Management Inc. (2.68%), Artal Group S.A. (1.86%) and Eventide Asset Management LLC (1.16%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.
Which major investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Westfield Capital Management Co. LP, Eventide Asset Management LLC, American Century Companies Inc., Prudential Financial Inc., Artisan Partners Limited Partnership, Candriam Luxembourg S.C.A. and Citigroup Inc.. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.
Which major investors are buying Acceleron Pharma stock?
XLRN stock was acquired by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, DekaBank Deutsche Girozentrale, Federated Investors Inc. PA, PNC Financial Services Group Inc., UBS Group AG, Artal Group S.A., Tiverton Asset Management LLC and Lord Abbett & CO. LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $35.74.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $1.64 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acceleron Pharma (NASDAQ:XLRN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Acceleron Pharma in the last 12 months. Their average twelve-month price target is $51.0769, suggesting that the stock has a possible upside of 42.91%. The high price target for XLRN is $69.00 and the low price target for XLRN is $33.00. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.71 | 2.63 | 2.59 | 2.61 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $51.0769 | $47.7333 | $45.3333 | $45.3750 |
| Price Target Upside: | 42.91% upside | 17.54% upside | 0.76% upside | 32.99% upside |
Acceleron Pharma (NASDAQ:XLRN) Consensus Price Target History
Acceleron Pharma (NASDAQ:XLRN) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Acceleron Pharma (NASDAQ:XLRN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Acceleron Pharma (NASDAQ XLRN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 87.80%
Acceleron Pharma (NASDAQ XLRN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/3/2018 | John D Quisel | SVP | Sell | 1,204 | $38.40 | $46,233.60 | |  |
| 4/3/2018 | Kevin F Mclaughlin | CFO | Sell | 4,000 | $38.45 | $153,800.00 | | |
| 4/3/2018 | Matthew L Sherman | EVP | Sell | 4,600 | $38.43 | $176,778.00 | | |
| 3/6/2018 | Richard F Pops | Director | Sell | 37,500 | $41.42 | $1,553,250.00 | 68,750 | |
| 1/12/2018 | Christopher Rovaldi | SVP | Sell | 11,000 | $45.00 | $495,000.00 | 35,701 | |
| 1/4/2018 | Kevin F Mclaughlin | CFO | Sell | 19,000 | $42.89 | $814,910.00 | 45,300 | |
| 1/3/2018 | Christopher Rovaldi | SVP | Sell | 2,266 | $42.42 | $96,123.72 | 52,977 | |
| 1/3/2018 | Matthew L Sherman | EVP | Sell | 4,633 | $42.71 | $197,875.43 | 77,700 | |
| 1/2/2018 | Kevin F Mclaughlin | CFO | Sell | 4,000 | $42.42 | $169,680.00 | 45,300 | |
| 12/15/2017 | Jean George | Director | Sell | 105,122 | $35.73 | $3,756,009.06 | 1,250 | |
| 9/25/2017 | Corp /De/ Celgene | Major Shareholder | Buy | 745,592 | $37.00 | $27,586,904.00 | 6,118,479 | |
| 9/13/2017 | John D Quisel | SVP | Sell | 5,113 | $38.42 | $196,441.46 | 57,918 | |
| 9/12/2017 | Christopher Rovaldi | SVP | Sell | 14,000 | $38.41 | $537,740.00 | 28,232 | |
| 9/12/2017 | Kevin F Mclaughlin | CFO | Sell | 16,000 | $38.41 | $614,560.00 | 50,810 | |
| 9/12/2017 | Matthew L Sherman | EVP | Sell | 18,400 | $38.41 | $706,744.00 | 79,750 | |
| 8/8/2017 | Ravindra Kumar | SVP | Sell | 13,065 | $35.41 | $462,631.65 | 108,392 | |
| 7/5/2017 | Kevin F Mclaughlin | CFO | Sell | 34,400 | $32.00 | $1,100,800.00 | 80,950 | |
| 7/5/2017 | Matthew L Sherman | EVP | Sell | 16,000 | $32.00 | $512,000.00 | 112,400 | |
| 7/5/2017 | Ravindra Kumar | SVP | Sell | 937 | $32.00 | $29,984.00 | 96,264 | |
| 1/4/2017 | Kevin F Mclaughlin | CFO | Sell | 1,700 | $27.45 | $46,665.00 | 72,200 | |
| 1/4/2017 | Matthew L Sherman | EVP | Sell | 2,000 | $27.46 | $54,920.00 | 98,100 | |
| 1/4/2017 | Steven D Ertel | COO | Sell | 2,500 | $27.44 | $68,600.00 | 130,977 | |
| 12/30/2016 | Joseph S Zakrzewski | Director | Buy | 4,000 | $25.50 | $102,000.00 | 4,000 | |
| 12/8/2016 | Terrance Mcguire | Director | Sell | 34,928 | $30.96 | $1,081,370.88 | 1,624 | |
| 11/17/2016 | Jean George | Director | Sell | 453,505 | $38.39 | $17,410,056.95 | | |
| 10/10/2016 | Ravindra Kumar | SVP | Sell | 52,486 | $33.92 | $1,780,325.12 | 91,875 | |
| 9/30/2016 | Jean George | Director | Sell | 857,145 | $35.50 | $30,428,647.50 | | |
| 9/21/2016 | John D Quisel | SVP | Sell | 45,952 | $38.05 | $1,748,473.60 | 77,004 | |
| 9/12/2016 | John D Quisel | SVP | Sell | 21,438 | $32.14 | $689,017.32 | 86,723 | |
| 7/6/2016 | John L Knopf | CEO | Sell | 100,000 | $33.87 | $3,387,000.00 | 147,106 | |
| 7/5/2016 | John L Knopf | CEO | Sell | 30,501 | $33.26 | $1,014,463.26 | 147,106 | |
| 7/5/2016 | Steven D Ertel | COO | Sell | 32,270 | $34.56 | $1,115,251.20 | 137,365 | |
| 7/1/2016 | John L Knopf | CEO | Sell | 28,022 | $34.72 | $972,923.84 | 147,106 | |
| 7/1/2016 | Kevin F Mclaughlin | CFO | Sell | 25,300 | $34.66 | $876,898.00 | 82,900 | |
| 7/1/2016 | Matthew L Sherman | EVP | Sell | 26,000 | $34.74 | $903,240.00 | 91,500 | |
| 7/1/2016 | Steven D Ertel | COO | Sell | 28,304 | $34.77 | $984,130.08 | 137,365 | |
| 5/20/2016 | John L Knopf | CEO | Sell | 100,000 | $33.07 | $3,307,000.00 | 160,674 | |
| 4/7/2016 | Matthew L Sherman | EVP | Sell | 26,000 | $32.00 | $832,000.00 | 95,524 | |
| 4/7/2016 | Steven D Ertel | COO | Sell | 32,270 | $32.00 | $1,032,640.00 | 131,098 | |
| 1/11/2016 | Corp /De/ Celgene | Major Shareholder | Buy | 800,000 | $40.00 | $32,000,000.00 | 5,372,887 | |
| 10/15/2015 | Matthew L. Sherman | EVP | Sell | 6,000 | $23.28 | $139,680.00 | 91,604 | |
| 10/7/2015 | John L. Knopf | CEO | Sell | 19,000 | $24.38 | $463,220.00 | 119,084 | |
| 10/7/2015 | Kevin F. Mclaughlin | CFO | Sell | 7,000 | $24.38 | $170,660.00 | 80,000 | |
| 9/16/2015 | Matthew L. Sherman | EVP | Sell | 2,000 | $33.24 | $66,480.00 | 96,404 | |
| 9/15/2015 | Ravindra Kumar | VP | Sell | 33,000 | $35.00 | $1,155,000.00 | 56,685 | |
| 9/15/2015 | Steven D. Ertel | COO | Sell | 2,000 | $33.61 | $67,220.00 | 119,656 | |
| 9/14/2015 | John D. Quisel | SVP | Sell | 5,500 | $33.35 | $183,425.00 | 76,123 | |
| 9/8/2015 | John L. Knopf | CEO | Sell | 19,000 | $30.20 | $573,800.00 | 21,584 | |
| 9/8/2015 | Kevin F. Mclaughlin | CFO | Sell | 6,500 | $30.16 | $196,040.00 | 40,000 | |
| 8/18/2015 | Matthew L Sherman | EVP | Sell | 7,000 | $31.13 | $217,910.00 | | |
| 8/14/2015 | John D Quisel | SVP | Sell | 5,500 | $30.83 | $169,565.00 | | |
| 7/20/2015 | Matthew L Sherman | EVP | Sell | 6,000 | $32.46 | $194,760.00 | | |
| 7/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $31.38 | $62,760.00 | | |
| 7/14/2015 | John D Quisel | SVP | Sell | 5,500 | $30.00 | $165,000.00 | | |
| 7/7/2015 | John L Knopf | CEO | Sell | 19,000 | $29.70 | $564,300.00 | | |
| 7/7/2015 | Kevin F Mclaughlin | CFO | Sell | 7,000 | $29.70 | $207,900.00 | | |
| 6/18/2015 | Matthew L Sherman | EVP | Sell | 7,000 | $31.54 | $220,780.00 | | |
| 6/15/2015 | John D Quisel | SVP | Sell | 5,500 | $31.13 | $171,215.00 | | |
| 6/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $31.11 | $62,220.00 | | |
| 6/8/2015 | John L Knopf | CEO | Sell | 19,000 | $32.51 | $617,690.00 | | |
| 6/8/2015 | Kevin F Mclaughlin | CFO | Sell | 6,500 | $32.49 | $211,185.00 | | |
| 5/18/2015 | Matthew L Sherman | EVP | Sell | 7,000 | $32.37 | $226,590.00 | | |
| 5/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $31.49 | $62,980.00 | | |
| 4/20/2015 | Matthew L Sherman | EVP | Sell | 5,000 | $33.52 | $167,600.00 | | |
| 4/15/2015 | Steven D Ertel | COO | Sell | 2,000 | $33.58 | $67,160.00 | | |
| 4/7/2015 | John L Knopf | CEO | Sell | 20,000 | $34.87 | $697,400.00 | | |
| 4/7/2015 | Kevin F Mclaughlin | CFO | Sell | 7,000 | $34.88 | $244,160.00 | | |
| 3/18/2015 | Matthew L Sherman | EVP | Sell | 6,000 | $41.18 | $247,080.00 | | |
| 3/16/2015 | John D Quisel | SVP | Sell | 9,500 | $41.00 | $389,500.00 | | |
| 3/9/2015 | John L Knopf | CEO | Sell | 20,000 | $40.25 | $805,000.00 | | |
| 3/9/2015 | Kevin F Mclaughlin | CFO | Sell | 6,500 | $40.25 | $261,625.00 | | |
| 1/20/2015 | Matthew L Sherman | SVP | Sell | 7,000 | $41.64 | $291,480.00 | | |
| 1/15/2015 | Steven D Ertel | SVP | Sell | 2,000 | $40.58 | $81,160.00 | | |
| 1/12/2015 | Kevin F Mclaughlin | CFO | Sell | 2,000 | $40.66 | $81,320.00 | | |
| 1/12/2015 | Ravindra Kumar | VP | Sell | 1,500 | $40.80 | $61,200.00 | | |
| 1/7/2015 | John L Knopf | CEO | Sell | 20,000 | $39.62 | $792,400.00 | | |
| 1/7/2015 | Kevin F Mclaughlin | CFO | Sell | 5,000 | $39.46 | $197,300.00 | | |
| 1/2/2015 | Ravindra Kumar | VP | Sell | 4,000 | $38.46 | $153,840.00 | | |
| 1/2/2015 | Steven D Ertel | SVP | Sell | 5,000 | $38.47 | $192,350.00 | | |
| 12/23/2014 | Edwin M Kania Jr | Director | Sell | 54,350 | $38.00 | $2,065,300.00 | | |
| 12/18/2014 | Matthew L Sherman | SVP | Sell | 5,000 | $40.16 | $200,800.00 | | |
| 12/12/2014 | John D Quisel | SVP | Sell | 4,000 | $41.35 | $165,400.00 | | |
| 12/9/2014 | Jean George | Director | Sell | 97,407 | $44.90 | $4,373,574.30 | | |
| 12/8/2014 | John L Knopf | CEO | Sell | 20,000 | $43.99 | $879,800.00 | | |
| 12/8/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $44.02 | $440,200.00 | | |
| 12/8/2014 | Tom Maniatis | Director | Sell | 23,400 | $45.00 | $1,053,000.00 | | |
| 12/1/2014 | Ravindra Kumar | VP | Sell | 4,000 | $35.88 | $143,520.00 | | |
| 12/1/2014 | Steven D Ertel | SVP | Sell | 7,500 | $35.87 | $269,025.00 | | |
| 11/18/2014 | Matthew L Sherman | SVP | Sell | 5,082 | $33.76 | $171,568.32 | | |
| 11/13/2014 | Ravindra Kumar | VP | Sell | 16,000 | $34.53 | $552,480.00 | | |
| 10/28/2014 | Tom Maniatis | Director | Sell | 23,400 | $35.00 | $819,000.00 | | |
| 10/8/2014 | John L Knopf | CEO | Sell | 20,000 | $29.71 | $594,200.00 | | |
| 10/8/2014 | Matthew L Sherman | SVP | Sell | 5,082 | $29.50 | $149,919.00 | | |
| 10/7/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $29.25 | $292,500.00 | | |
| 10/1/2014 | Ravindra Kumar | VP | Sell | 11,000 | $29.89 | $328,790.00 | | |
| 10/1/2014 | Steven D Ertel | SVP | Sell | 10,000 | $29.66 | $296,600.00 | | |
| 9/30/2014 | John D Quisel | SVP | Sell | 7,000 | $30.01 | $210,070.00 | | |
| 9/18/2014 | Matthew L Sherman | SVP | Sell | 5,000 | $25.48 | $127,400.00 | | |
| 9/12/2014 | John D Quisel | SVP | Sell | 2,000 | $25.43 | $50,860.00 | | |
| 9/9/2014 | John L Knopf | CEO | Sell | 20,000 | $24.46 | $489,200.00 | | |
| 9/9/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $24.48 | $244,800.00 | | |
| 9/8/2014 | John L Knopf | CEO | Sell | 6,700 | $24.92 | $166,964.00 | | |
| 9/8/2014 | Kevin F Mclaughlin | CFO | Sell | 3,300 | $24.90 | $82,170.00 | | |
| 9/3/2014 | Matthew L Sherman | SVP | Sell | 5,000 | $25.82 | $129,100.00 | | |
| 8/18/2014 | Matthew L Sherman | SVP | Sell | 2,500 | $29.62 | $74,050.00 | | |
| 8/14/2014 | John D Quisel | SVP | Sell | 13,000 | $29.98 | $389,740.00 | | |
| 8/14/2014 | John L Knopf | CEO | Sell | 17,500 | $29.78 | $521,150.00 | | |
| 8/14/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $29.78 | $297,800.00 | | |
| 8/14/2014 | Ravindra Kumar | VP | Sell | 9,000 | $29.97 | $269,730.00 | | |
| 7/18/2014 | Matthew L Sherman | SVP | Sell | 2,500 | $26.22 | $65,550.00 | | |
| 7/14/2014 | John D Quisel | SVP | Sell | 5,000 | $29.73 | $148,650.00 | | |
| 7/9/2014 | Matthew L Sherman | SVP | Sell | 7,500 | $28.99 | $217,425.00 | | |
| 7/7/2014 | John L Knopf | CEO | Sell | 17,500 | $31.74 | $555,450.00 | | |
| 7/7/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $31.72 | $317,200.00 | | |
| 7/1/2014 | Ravindra Kumar | VP | Sell | 2,000 | $34.10 | $68,200.00 | | |
| 7/1/2014 | Steven D Ertel | SVP | Sell | 10,000 | $34.09 | $340,900.00 | | |
| 6/26/2014 | Jean George | Director | Sell | 10,491 | $35.01 | $367,289.91 | | |
| 6/24/2014 | Jean George | Director | Sell | 25,477 | $35.16 | $895,771.32 | | |
| 6/20/2014 | Ravindra Kumar | VP | Sell | 7,000 | $35.00 | $245,000.00 | | |
| 6/18/2014 | Matthew L Sherman | SVP | Sell | 2,500 | $34.42 | $86,050.00 | | |
| 6/13/2014 | John D Quisel | VP | Sell | 9,000 | $33.94 | $305,460.00 | | |
| 6/11/2014 | Matthew L Sherman | SVP | Sell | 7,500 | $33.23 | $249,225.00 | | |
| 6/9/2014 | John L Knopf | CEO | Sell | 15,000 | $31.65 | $474,750.00 | | |
| 6/9/2014 | Kevin F Mclaughlin | CFO | Sell | 10,000 | $31.65 | $316,500.00 | | |
| 5/19/2014 | John Knopf | CEO | Sell | 15,000 | $31.52 | $472,800.00 | 206,500 | |
| 5/19/2014 | John Quisel | VP | Sell | 9,000 | $31.43 | $282,870.00 | | |
| 5/19/2014 | Steven Ertel | SVP | Sell | 10,000 | $31.52 | $315,200.00 | 27,656 | |
| 5/5/2014 | Corp /De/ Celgene | major shareholder | Buy | 1,100,000 | $42.86 | $47,146,000.00 | 4,572,887 | |
| 5/5/2014 | Jean George | Director | Sell | 215,644 | $42.86 | $9,242,501.84 | | |
| 4/24/2014 | Edwin Kania, Jr. | Director | Sell | 1,000,000 | $32.05 | $32,050,000.00 | 4,867 | |
| 4/22/2014 | Ravindra Kumar | VP | Sell | 2,000 | $35.86 | $71,720.00 | 45,890 | |
| 4/22/2014 | Steven Ertel | SVP | Sell | 2,500 | $35.87 | $89,675.00 | 27,656 | |
| 1/28/2014 | Corp /De/ Celgene | Major Shareholder | Buy | 300,000 | $50.00 | $15,000,000.00 | | |
| 9/24/2013 | Corp /De/ Celgene | Major Shareholder | Buy | 666,667 | $15.00 | $10,000,005.00 | | |
(Data available from 1/1/2013 forward)
Acceleron Pharma (NASDAQ XLRN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
finance.yahoo.com - May 17 at 6:42 PM |
 | Acceleron Pharma's (XLRN) CEO Habib Dable on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 8:26 AM |
 | Oppenheimer Weighs in on Acceleron Pharma's Q2 2018 Earnings (XLRN)
www.americanbankingnews.com - May 11 at 8:15 AM |
| Piper Jaffray Comments on Acceleron Pharma's Q2 2018 Earnings (XLRN)
www.americanbankingnews.com - May 11 at 8:15 AM |
| Leerink Swann Equities Analysts Reduce Earnings Estimates for Acceleron Pharma (XLRN)
www.americanbankingnews.com - May 11 at 8:15 AM |
| Credit Suisse Group Analysts Give Acceleron Pharma (XLRN) a $55.00 Price Target
www.americanbankingnews.com - May 10 at 9:08 AM |
| HC Wainwright Raises Acceleron Pharma (XLRN) Price Target to $69.00
www.americanbankingnews.com - May 9 at 3:12 PM |
| Acceleron Pharma beats by $0.06, misses on revenue
seekingalpha.com - May 8 at 5:40 PM |
| Acceleron: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:40 PM |
| Acceleron Reports First Quarter 2018 Operating and Financial Results
finance.yahoo.com - May 8 at 5:40 PM |
| Acceleron Pharma (XLRN) Releases Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - May 8 at 5:24 PM |
| Brokerages Expect Acceleron Pharma (XLRN) Will Announce Quarterly Sales of $4.35 Million
www.americanbankingnews.com - May 5 at 2:53 AM |
| Acceleron Pharma (XLRN) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - May 5 at 12:29 AM |
| Traders Buy Large Volume of Put Options on Acceleron Pharma (XLRN)
www.americanbankingnews.com - May 4 at 8:46 AM |
| -$0.64 Earnings Per Share Expected for Acceleron Pharma (XLRN) This Quarter
www.americanbankingnews.com - May 3 at 9:31 PM |
| Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase — New Research Emphasizes Economic Growth
finance.yahoo.com - May 3 at 8:16 AM |
| Acceleron Pharma Sees Unusually Large Options Volume (XLRN)
www.americanbankingnews.com - May 3 at 8:15 AM |
 | Acceleron Pharma (XLRN) Granted FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
www.streetinsider.com - May 2 at 5:37 PM |
| Acceleron to Participate in Two Healthcare Investor Conferences in May
finance.yahoo.com - May 2 at 8:20 AM |
| Acceleron's ACE-083 Fast Track'd for type of muscular dystrophy
seekingalpha.com - May 1 at 5:18 PM |
| Acceleron Pharma (XLRN) Receives Hold Rating from Cann
www.americanbankingnews.com - May 1 at 1:28 PM |
| Acceleron Pharma (XLRN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 11:34 AM |
| Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018
finance.yahoo.com - April 30 at 8:23 AM |
| Acceleron Pharma (XLRN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 7:22 AM |
| Acceleron Pharma (XLRN) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - April 26 at 4:22 PM |
| Acceleron Pharma (XLRN) Cut to "Hold" at ValuEngine
www.americanbankingnews.com - April 26 at 1:32 PM |
| Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 26 at 8:16 AM |
| Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
finance.yahoo.com - April 26 at 8:16 AM |
| 2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
finance.yahoo.com - April 22 at 8:17 AM |
| Acceleron Pharma's (XLRN) Hold Rating Reaffirmed at Cann
www.americanbankingnews.com - April 20 at 10:18 PM |
| Acceleron Pharma (XLRN) Receives "Buy" Rating from Credit Suisse Group
www.americanbankingnews.com - April 19 at 11:52 PM |
| Acceleron Pharma (XLRN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 19 at 9:23 AM |
| Acceleron Pharma (XLRN) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 18 at 10:23 AM |
| $4.35 Million in Sales Expected for Acceleron Pharma (XLRN) This Quarter
www.americanbankingnews.com - April 18 at 2:46 AM |
| Acceleron Pharma (XLRN) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 16 at 3:14 PM |
| Acceleron Pharma (XLRN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:26 PM |
| Q4 Biotech Catalyst Watchlist: Phase 3 Clinical Trials
seekingalpha.com - April 10 at 8:25 AM |
| Acceleron Pharma (XLRN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 12:10 PM |
| Acceleron Pharma (XLRN) SVP John D. Quisel Sells 1,204 Shares
www.americanbankingnews.com - April 4 at 11:37 PM |
| Acceleron Pharma (XLRN) EVP Sells $176,778.00 in Stock
www.americanbankingnews.com - April 4 at 11:16 PM |
| Kevin F. Mclaughlin Sells 4,000 Shares of Acceleron Pharma (XLRN) Stock
www.americanbankingnews.com - April 4 at 11:16 PM |
| Acceleron Pharma (XLRN) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 10:26 PM |
| Acceleron Pharma (XLRN) Expected to Post Quarterly Sales of $4.35 Million
www.americanbankingnews.com - April 1 at 2:36 AM |
| Acceleron Pharma (XLRN) Expected to Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - March 30 at 5:14 PM |
| Oppenheimer Reaffirms "Hold" Rating for Acceleron Pharma (XLRN)
www.americanbankingnews.com - March 30 at 12:04 PM |
| Acceleron Pharma (XLRN) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 30 at 11:06 AM |
| Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $4.35 Million
www.americanbankingnews.com - March 15 at 4:42 AM |
| Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial
finance.yahoo.com - March 12 at 9:01 AM |
| Acceleron Pharma Inc (XLRN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 1:18 PM |
| Acceleron Pharma Inc (XLRN) Director Richard F. Pops Sells 37,500 Shares
www.americanbankingnews.com - March 8 at 6:13 PM |
Acceleron Pharma (NASDAQ:XLRN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Acceleron Pharma (NASDAQ:XLRN) Income Statement, Balance Sheet and Cash Flow Statement
Acceleron Pharma (NASDAQ XLRN) Stock Chart for Monday, May, 21, 2018
Loading chart…
